Treace Medical Reports Five-Year Results for Lapiplasty Bunion Procedure
Treace Medical (NASDAQ: TMCI) announced five-year results from its ALIGN3D study on September 17, showing low recurrence rates of the Lapiplasty bunion correction procedure. The final analysis included data from approximately 79% of original participants and reported a radiographic recurrence rate of 0.8%, using stricter criteria (hallux valgus angle >20 degrees), and 5.3% with looser thresholds (>15 degrees). These results suggest durable outcomes, which could support broader surgeon adoption if the evidence is compelling enough. The company also noted sustained patient-reported improvements over five years. However, challenges remain in translating this clinical data into commercial success. While some surgeons are already adopting newer bunion systems from Treace, the lack of a randomized control group and missing follow-up for 36 patients raise questions about generalizability and interpretation. Despite positive results, second-quarter revenue declined by 4% to $45.4 million, with gross margin falling slightly as well. The company reported a GAAP net loss of $15.9 million during the same period.
Tickers: $TMCI
Topics: ALIGN3D study bunion surgery Lapiplasty Treace Medical